Holiday Notification: Cayman Chemical will be closed Monday, May 28, 2012, in observance of the Memorial Day holiday.
More…
Please feel free to continue placing orders via our website or via fax at 734-971-3640. You may send an email to customer service at custserv@caymanchem.com , or to technical support at techserv@caymanchem.com which we will respond to the next business day. Cayman will resume regular business hours and shipping schedules on Tuesday, May 29, 2012. Thank you for your patience and understanding.
The effects of Leukotriene B4 (LTB4) are mediated by two known receptors, BLT1 and BLT2.1,2 LTB4 is a high affinity ligand for BLT1, and many of its pro-inflammatory effects are believed to be transduced through this receptor. The BLT2 is more enigmatic, in that LTB4 is not a high-affinity ligand, nor is it clear that BLT2 activation promotes inflammation. LTB4 ethanolamide (LTB4-EA) is a theoretical 5-LO metabolite of arachidonoyl ethanolamide (AEA). In CHO cells transfected with human BLTR1, LTB4-EA was a potent antagonist with about three times greater affinity for the receptor than LTB4 (Ki = 1.22 nM versus 3.88 nM). LTB4-EA antagonizes the LTB4-induced contractions of guinea pig lung parenchyma with an EC50 of 10 nM.3 LTB4-EA thus represents a potential endogenous anti-inflammatory compound functioning as a natural antagonist of BLTR1.
1
Yokomizo, T., Izumi, T., Chang, K., et al. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature387620-624(1997).
2
Yokomizo, T., Kato, K., Terawaki, K., et al. A second leukotriene B4 receptor, BLT2: A new therapeutic target in inflammation and immunological disorders. J Exp Med193421-431(2000).
3
McHugh, D., McMaster, S., and Ross, R. Pharmacological characterization of LTB4 ethanolamide: Interaction with leukotriene (BLT) and vanilloid (TRPV1) receptors. 121(2003).
Yokomizo, T., Izumi, T., Chang, K., et al. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature387620-624(1997).
Yokomizo, T., Kato, K., Terawaki, K., et al. A second leukotriene B4 receptor, BLT2: A new therapeutic target in inflammation and immunological disorders. J Exp Med193421-431(2000).
McHugh, D., McMaster, S., and Ross, R. Pharmacological characterization of LTB4 ethanolamide: Interaction with leukotriene (BLT) and vanilloid (TRPV1) receptors. 121(2003).
Leukotriene B4 Ethanolamide is available in the following screening
library: